Speaker:

Laura Tafe, M.D.

Moderator:

Jonathan Nowak, M.D.,Ph.D.

 

This product includes the webinar and SAM credit


Description: This webinar will act as an overview and update regarding the use of Tumor Mutational Burden (TMB) as a diagnostic and prognostic tool. Advances in massively parallel sequencing technologies has facilitated the large scale examination of the mutational profile of tumors. Best practices with regard to elaboration of these techniques is evolving as is the correlation of results with clinical outcomes. This presentation will provide additional information regarding the newest innovations as well as implications for TMB testing, interpretation, and reporting. Some clinical applications and challenges will be discussed.

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: December 31, 2021

Maximum SAM credit available: 1.0

This webinar is part 1 of a two-part series exploring the role of TMB testing in relationship to other tumor biomarkers as well as the standardization of TMB testing.


This program has been supported through an educational grant from Bristol-Myers Squibb.


AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits.Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 

Course Information
Course Date:
June 06, 2019
Course Objectives
  • Elaborate on the advantages and limitations of TMB molecular diagnostic results.
  • Describe the current use of TMB to guide diagnosis and treatment.
  • Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Pre-Test
Updates on Tumor Mutational Burden and the Immunotherapy Biomarker Landscape
Post-Test
How to Access SAM Credit
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Products
Tafe (+SAM)
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00